Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relmada Therapeutics (RLMD) Liabilities and Shareholders Equity (2016 - 2026)

Relmada Therapeutics has reported Liabilities and Shareholders Equity over the past 3 years, most recently at $10000.0 for Q1 2014.

  • Quarterly Liabilities and Shareholders Equity fell 1.9% to $10000.0 in Q1 2014 from the year-ago period, while the trailing twelve-month figure was $47042.0 through Feb 2014, up 64.78% year-over-year, with the annual reading at $20009.0 for FY2013, 9.02% up from the prior year.
  • Liabilities and Shareholders Equity was $10000.0 for Q1 2014 at Relmada Therapeutics, down from $12300.0 in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $20009.0 in Q3 2013 and troughed at $4733.0 in Q2 2013.
  • The 3-year median for Liabilities and Shareholders Equity is $11247.0 (2013), against an average of $12598.3.
  • Year-over-year, Liabilities and Shareholders Equity increased 9.02% in 2013 and then decreased 1.9% in 2014.
  • A 3-year view of Liabilities and Shareholders Equity shows it stood at $18354.0 in 2012, then crashed by 32.98% to $12300.0 in 2013, then fell by 18.7% to $10000.0 in 2014.
  • Per Business Quant, the three most recent readings for RLMD's Liabilities and Shareholders Equity are $10000.0 (Q1 2014), $12300.0 (Q4 2013), and $20009.0 (Q3 2013).